Neurocrine Biosciences Inc (NBIX)

Working capital turnover

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Revenue (ttm) US$ in thousands 2,355,300 2,241,400 2,117,000 1,978,200 1,882,900 1,779,300 1,668,300 1,522,900 1,411,600 1,306,100 1,208,800 1,185,500 1,107,700 1,050,200 1,010,800 1,022,200 1,020,900 1,017,010 981,066 862,604
Total current assets US$ in thousands 1,724,700 1,876,600 1,669,800 1,799,000 1,607,000 1,649,900 1,496,600 1,432,800 1,453,500 1,205,500 1,019,300 1,018,200 972,800 1,005,700 1,110,100 1,085,400 1,016,200 1,156,900 1,146,200 968,200
Total current liabilities US$ in thousands 507,700 429,700 398,500 712,900 654,800 691,600 582,500 374,100 537,700 485,100 285,700 253,500 245,800 225,900 212,900 190,000 186,500 611,000 573,000 140,300
Working capital turnover 1.94 1.55 1.67 1.82 1.98 1.86 1.83 1.44 1.54 1.81 1.65 1.55 1.52 1.35 1.13 1.14 1.23 1.86 1.71 1.04

December 31, 2024 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $2,355,300K ÷ ($1,724,700K – $507,700K)
= 1.94

The working capital turnover ratio measures how efficiently a company is using its working capital to generate sales. Neurocrine Biosciences Inc's working capital turnover has fluctuated over the past few years, ranging from a low of 1.04 in March 2020 to a high of 1.98 in December 2023.

Overall, the company's working capital turnover ratio has generally been within a moderate range, indicating that Neurocrine Biosciences Inc is effectively utilizing its working capital to generate revenue. It is important for the company to continue monitoring and maintaining this ratio to ensure optimal efficiency in its operations.